New combo offers hope for lung cancer patients resistant to targeted drugs
NCT ID NCT04042558
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tested a combination of chemotherapy (platinum and pemetrexed) plus an immunotherapy drug (atezolizumab), with or without another drug (bevacizumab), in 150 adults with advanced non-squamous lung cancer that has specific gene changes (EGFR, ALK, or ROS1) and has stopped responding to targeted therapies. The main goal was to see how many patients' tumors shrank or disappeared. This approach aims to control the disease, not cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHD Vendée La Roche sur Yon
La Roche-sur-Yon, France
-
CHIC
Créteil, France
-
CHR Orléans
Orléans, France
-
CHU
Angers, France
-
CHU
Grenoble, France
-
CHU
Lille, France
-
CHU
Pierre-Bénite, France
-
CHU
Rennes, France
-
CHU
Rouen, France
-
CHU
Toulouse, France
-
CHU Gabriel MONTPIED
Clermont-Ferrand, France
-
CHU Limoges
Limoges, France
-
CHU Lyon Louis Pradel
Bron, France
-
CHU Lyon, Croix-Rousse,
Lyon, France
-
CHU Réunion St Denis
La Réunion, France
-
CHU Réunion St Pierre
La Réunion, France
-
CHU-Hôpital MORVAN
Brest, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Hospitalier
Annecy, France
-
Centre Hospitalier
Villefranche, France
-
Centre Hospitalier Bretagne Atlantique
Vannes, France
-
Centre Léon Bérard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
HIA Percy
Percy, France
-
HIA R.Picqué
Villenave-d'Ornon, France
-
HIA St Anne
Toulon, France
-
Hopital Foch
Paris, France
-
Hôpital Haut Lévêque,Centre François Magendie
Pessac, France
-
Hôpital Nord
Marseille, France
-
ICLN, St Priez en Jarez
Saint-Priest-en-Jarez, France
-
institut Curie
Paris, France
Conditions
Explore the condition pages connected to this study.